Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice

Neurochemistry International

Volumn 49, Issue 2, 2006, Pages 190-194

  Morgan, Dave ^a  

^a Department of Pharmacology   (United States)

Author keywords

Amyloid; Transgenic, APP, Fc gamma receptor, CD45

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID PRECURSOR PROTEIN;

ALZHEIMER DISEASE; AMNESIA; ARTICLE; CELL ACTIVATION; CORRELATION ANALYSIS; DISEASE ASSOCIATION; GENE OVEREXPRESSION; HIPPOCAMPUS; IMMUNIZATION; IMMUNOTHERAPY; MICROGLIA; NONHUMAN; PARENCHYMA; PHENOTYPE; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES; BRAIN; DISEASE MODELS, ANIMAL; ENCEPHALITIS; GLIOSIS; HUMANS; IMMUNIZATION, PASSIVE; MICE; MICE, TRANSGENIC; MICROGLIA;

MUS MUSCULUS;

EID: 33744982670     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2006.03.017     Document Type: Article

References (34)

1. Adlard P.A., Perreau V.M., Pop V., and Cotman C.W. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J. Neurosci. 25 (2005) 4217-4221
2. Bacskai B.J., Kajdasz S.T., Christie R.H., Carter C., Games D., Seubert P., Schenk D., and Hyman B. Imaging of amyloid-β deposits in living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 7 (2001) 369-372
3. Bard F., Barbour R., Cannon C., Carretto R., Fox M., Games D., Guido T., Hoenow K., Hu K., Johnson-Wood K., Khan K., Kholodenko D., Lee C., Lee M., Motter R., Nguyen M., Reed A., Schenk D., Tang P., Vasquez N., Seubert P., and Yednock T. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci., U.S.A. 100 (2003) 2023-2028
4. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., and Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6 (2000) 916-919
5. Chauhan N.B., and Siegel G.J. Reversal of amyloid beta toxicity in Alzheimer's disease model Tg2576 by intraventricular antiamyloid beta antibody. J. Neurosci. Res. 69 (2002) 10-23
6. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., and Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci., U.S.A. 98 (2001) 8850-8855
7. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., DeLong C.A., Wu S., Wu X., Holtzman D.M., and Paul S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5 (2002) 452-457
8. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Perez-tur J., Hutton M., Buee L., Harigaya Y., Yager D., Morgan D., Gordon M.N., Holcomb L., Refolo L., Zenk B., Hardy J., and Younkin S. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383 (1996) 710-713
9. Duffield J.S. The inflammatory macrophage: a story of Jekyll and Hyde. Clin. Sci. (Lond) 104 (2003) 27-38
10. Ferrer I., Boada R.M., Sanchez Guerra M.L., Rey M.J., and Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 14 (2004) 11-20
11. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., and Gillespie F. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373 (1995) 523-527
12. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira M.B., Forette F., and Orgogozo J.M. AN1792(QS-21)-201 Study Team. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 (2005) 1553-1562
13. Gordon M.N., Holcomb L.A., Jantzen P.T., DiCarlo G., Wilcock D., Boyett K.L., Connor K., Melachrino J.O., O'Callaghan J.P., and Morgan D. Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1 + APP mouse. Exp. Neurol. 173 (2002) 183-195
14. Gordon M.N., King D.L., Diamond D.M., Jantzen P.T., Boyett K.L., Hope C.E., Hatcher J.M., DiCarlo G., Gottschal P., Morgan D., and Arendash G.W. Correlation between cognitive deficits and Aβ deposits in transgenic APP + PS1 mice. Neurobiol. Aging 22 (2001) 377-385
15. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
16. Hock C., Konietzko U., Papassotiropoulos A., Wollmer A., Streffer J., Von Rotz R.C., Davey G., Moritz E., and Nitsch R.M. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat. Med. 8 (2002) 1270-1275
17. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., Lemke U., Henke K., Moritz E., Garcia E., Wollmer M.A., Umbricht D., de Quervain D.J., Hofmann M., Maddalena A., Papassotiropoulos A., and Nitsch R.M. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38 (2003) 547-554
18. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., and Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274 (1996) 99-102
19. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., George-Hyslop P., and Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 (2000) 979-982
20. Kotilinek L.A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B.T., Younkin S., and Ashe K.H. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22 (2002) 6331-6335
21. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., and Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25 (2004) 677-686
22. Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C., Seubert P., Games D., Kirby L., and Schenk D. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64 (2005) 129-131
23. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., and Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000) 982-985
24. Morgan D., Gordon M., Tan J., Wilcock D., and Rojiani A.M. Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition. Implications for Alzheimer's therapeutics. J. Neuropathol. Exp. Neur. 64 (2005) 743-753
25. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., and Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9 (2003) 448-452
26. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A., and Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61 (2003) 46-54
27. Patel N.V., Gordon M.N., Connor K.E., Good R.A., Engelman R.W., Mason J., Morgan D.G., Morgan T.E., and Finch C.E. Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. Neurobiol. Aging 26 (2005) 995-1000
28. Refolo L.M., Pappolla M.A., Malester B., LaFrancois J., Bryant-Thomas T., Wang R., Tint G.S., Sambamurti K., and Duff K. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7 (2000) 321-331
29. Roos A., Xu W., Castellano G., Nauta A.J., Garred P., Daha M.R., and van Kooten C. Mini-review: a pivotal role for innate immunity in the clearance of apoptotic cells. Eur. J. Immunol. 34 (2004) 921-929
30. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., and Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
31. Wilcock D.M., DiCarlo G., Henderson D., Jackson J., Clarke K., Ugen K.E., Gordon M.N., and Morgan D. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci. 23 (2003) 3745-3751
32. Wilcock D.M., Munireddy S.K., Rosenthal A., Ugen K.E., Gordon M.N., and Morgan D. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol. Dis. 15 (2004) 11-20
33. Wilcock D.M., Rojiani A., Rosenthal A., Levkowitz G., Subbarao S., Alamed J., Wilson D., Wilson N., Freeman M.J., Gordon M.N., and Morgan D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci. 24 (2004) 6144-6151
34. Wilcock D.M., Rojiani A., Rosenthal A., Subbarao S., Freeman M.J., Gordon M.N., and Morgan D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinfl. 1 (2004) 24